Wanbury Limited Receives Key Clearance from USFDA for Multiple ANDAs
Wanbury Limited has received the 'No DMF deficiency letter' from the U.S. Food and Drug Administration (USFDA) regarding multiple Abbreviated New Drug Applications (ANDAs). This clearance pertains to formulations utilizing Metformin HCl API sourced by Wanbury for various products.
The receipt of this crucial documentation signifies a significant milestone for the company, affirming the status of its applications with the USFDA concerning the relevant ANDAs.
In addition to these clearances, Wanbury Limited is actively expanding its global footprint. The company has expanded business opportunities in South Korea through the filing of a DMF pertaining to one additional API.
Wanbury reaffirmed its commitment to supply high-quality APIs to the new market, emphasizing support for human well-being through its pharmaceutical products.
WANBURY Stock Price Movement
Shares of Wanbury Limited are edging higher to ₹309.45 as of 10:06 AM, gaining 1.16% in live trading this morning. The stock has seen brisk activity, with 79,299 shares traded so far into the ongoing market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.